Publications & Abstracts

Ezurpimtrostat, A Palmitoyl‑Protein Thioesterase‑1 Inhibitor, Combined with PD‑1 Inhibition Provides CD8+ Lymphocyte Repopulation in Hepatocellular Carcinoma

Bestion EN,Rachid M, Tijeras-Raballand A, Roth G, Decaens T, Ansaldi C, ,Mezouar S, Raymond E, Halfon P

Targeted Oncology, 2023.

First-in-human effects of PPT1 inhibition using the oral treatment with GNS561/ ezurpimtrostat in patients with primary and secondary liver cancers

Harding JJ, Awada A, Roth G, Decaens T, Merle P, Kotecki N, Dreyer C, Ansaldi C, Rachid M, Mezouar S, Menut A, Bestion EN, Paradis V, Halfon P, Abou-Alfa GK, Raymond E

Liver Cancer Journal, 2022.

GNS561, a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition

E. Bestion, Z. Macek Jilkova, JL Mège, M. Novello, K. Kurma, ST Ahmad Pour, G. Lalmanach, L. Vanderlynden, L. Fizanne, F. Bassissi, M. Rachid, J. Tracz, J. Boursier, J. Courcambeck, C. Serdjebi, C. Ansaldi, T. Decaens, P. Halfon and S. Brun

Therapeutic Advances in Chronic Disease. 2020, Vol. 11: 1-14.

GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma

S. Brun, F. Bassissi, C. Serdjebi, M. Novello, J. Tracz, F. Autelitano, M. Guillemot, P. Fabre, J. Courcambeck, C. Ansaldi, E. Raymond, P. Halfon

Invest New Drugs. 2019 Feb 19 PMID: 30778887

Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model

 S. Lagaye, S. Brun, J. Gaston, H. Shen, R. Stranska, C. Camus, C. Dubray, G. Rousseau, PP. Massault, J. Courcambeck, F. Bassisi, P. Halfon, S. Pol 

World J Hepatol. 2016 Jul 28;8(21):902-14

GNS561, une nouvelle molécule orale en stade clinique, seul ou en combinaison avec un inhibiteur de PD-1, montre une activé anti-tumorale remarquable dans un modèle de carcinome hépatocellulaire chez la souris transgénique immunocompétente (ASV-B) (CO-015)

M. Rachid

85èmes Journées Scientifiques de l’AFEF – October 2019

GNS561 : a new quinoline derivative with high efficacy on cancer stem cells in liver metastases from colorectal cancer and hepatocellular carcinoma 

S. Brun

38th EORTC-PAMM Winter Meeting – March 2017

Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients (0319P)

G. K. Abou-Alfa, J. Harding, A. Awada, N. Kotecki, P. Aftimos, T. Decaens, C. Dreyer, P. Merle, C. Ansaldi, M. Rachid, C. Serdjebi, S. Brun, P. Halfon, E. Raymond

AASLD – November 2019

Additive effect of GNS561, a new lysosomotropic small molecule in combination with cisplatin or gemcitabine for the treatment of intrahepatic cholangiocarcinoma (0352P)

C. Ansaldi, S. Brun, F. Bassissi, C. Serdjebi, M. Novello, J. Tracz, F. Autelitano, M. Guillemot, P. Fabre, M. Rachid, J. Courcambeck, E. Raymond, P. Halfon

AASLD – November 2019

GNS561, a new oral clinical-stage small molecule combined with a PD-1 inhibitor showed remarkable anti-tumor effects in a transgenic immunocompetent hepatocellular carcinoma mouse model (ASV-B) (1193P)

P. Halfon, M. Rachid, C. Serdjebi, A. Tijeras-Rablland, S. Brun, C. Ansaldi, E. Raymond

AASLD – November 2019

GNS561, a new lysosomotropic small molecule, for the treatment of liver fibrosis (2143P)

C. Ansaldi, E. Bestion, J. Boursier, G. Lalmanach, M. Novello, Z. M. Jilkova, F. Bassissi, L. Vanderlynde, M. Rachid, L. Fizanne, J. Tracz, J. Courcambeck, C. Serdjebi, T. Decaens, P. Halfon, S.

AASLD – November 2019

Résultats préliminaires de tolérance et pharmacocinétique d’une étude de Phase 1b « First-in-man » avec GNS561,
nouvel agent lysosomotropique oral, chez des patients atteints de cancer primaire du foie à un stade avancé
(P036)

T. Decaens, A. H. Awada, J. Harding, N. Kotecki, P. Aftimos, C. Dreyer, C. Ansaldi, M. Rachid, C. Serdjebi, S. Brun, P. Halfon, G. K. Abou-Alfa, E. Raymond

85èmes Journées Scientifiques de l’AFEF – October 2019

GNS561, un nouvel agent lysosomotropique dans le traitement de la fibrose hépatique (P058)

E. Bestion, J. Boursier, G. Lalmanach, M. Novello, Z. Macek Jilkova, F. Bassissi, L. Vanderlynde, M. Rachid, L. Fizanne, J. Tracz, J. Courcambeck, C. Serdjebi, C. Ansaldi, T. Decaens, P. Halfon, S. Brun

85èmes Journées Scientifiques de l’AFEF – October 2019

GNS561 seul ou en combinaison avec le cisplatine ou la gemcitabine dans le traitement du cholangiocarcinome intra-hépatique (P037)

S. Brun, C. Ansaldi, F. Bassissi, C. Serdjebi, M. Novello, J. Tracz, F. Autelitano, M. Guillemot, P. Fabre, M. Rachid, J. Courcambeck, E. Raymond, P. Halfon

85èmes Journées Scientifiques de l’AFEF – October 2019

Preliminary Safety and Pharmacokinetics of a New Lysosomotropic Oral Agent, GNS561, in a First-in-Human Study in Advanced Primary Liver Cancer Patients (Abstract #2848, 745P)

A. Awada, J. Harding, N. Kotecki, P. Aftimos, T. Decaens, C. Dreyer, C. Ansaldi, M. Rachid, C. Serdjebi, S. Brun, P. Halfon, G. Abou-Alfa, E. Raymond

ESMO Congress – September 2019